The Evaluation of Arg Expression in Dlbcl Staging



Mokarian F¹ ; Amani S² ; Kabiri Z² ; Salehi M² Show Affiliations
Source: Journal of Isfahan Medical School Published:2008

Abstract

Background: ARG is a proto-oncogene and a member of a tyrosine kinase proteins family. It has great importance in many cancers, but there is no conclusive evidence on its role in DLBCL staging. The aim of this study was to evaluate importance of ARG, in this cancer's staging Methods: Sixteen DLBCL and 4 reactive lymph node (as control group) samples, after staging using Ann Arbor staging system, were used in this study. Formaldehyde fixed paraffin embedded blocks were prepared from the samples. After the sectioning, all samples were hybridized with primary antibodies against ARG and GAPDH (as control house keep keeping gene). The slides were then washed and hybridized with fluorescently labeled secondary antibodies (ARG, green labeled and GAPDH, red). After capturing the pictures using CCD camera, the intensity of green and red colures was measured and the ratio between green/red, that demonstrate changes in ARG expression, were calculated. Findings: The mean ratio of green/red (ARG expression) was significantly different between reactive lymph node, stage I, II and III of DLBCL. ARG expression was different between all groups except for between stage III and VI of DLBCL. Conclusion: The observed changes in ARG expression is a potential biomarker for DLBCL staging. In addition specific inhibitors of ARG can be considered as new chemotherapy agents in the DLBCL treatment. © 2008, Isfahan University of Medical Sciences(IUMS). All rights reserved.